Kent E. Lieginger
Director/Board Member chez University of the Sciences in Philadelphia
Profil
Kent E.
Lieginger is an Independent Director at Achaogen, Inc. and a Trustee at the University of the Sciences in Philadelphia.
He was previously a Director at The Genentech Foundation from 2005 to 2012, and SVP-Managed Care & Customer Operations at Genentech, Inc. from 2010 to 2014.
He also held positions as Vice President at GSK Plc and Assistant Professor at the University of California.
Postes actifs de Kent E. Lieginger
| Sociétés | Poste | Début |
|---|---|---|
| University of the Sciences in Philadelphia | Director/Board Member | 01/01/2013 |
Anciens postes connus de Kent E. Lieginger
| Sociétés | Poste | Fin |
|---|---|---|
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Corporate Officer/Principal | 01/07/2014 |
| The Genentech Foundation | Director/Board Member | 01/01/2012 |
| University of California | Corporate Officer/Principal | - |
| GSK PLC | Corporate Officer/Principal | - |
| ACHAOGEN | Director/Board Member | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| GSK PLC | Health Technology |
| Entreprise privées | 3 |
|---|---|
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Health Technology |
Achaogen, Inc.
 Achaogen, Inc. Pharmaceuticals: MajorHealth Technology Achaogen, Inc. engages in developing and commercializing innovative antibacterial agents for multi-drug resistant gram-negative infections. The firm is also involved in the development of C-Scape, an orally administered antibiotic to address a serious unmet need for an effective oral treatment for patients with complicated urinary tract infections, including pyelonephritis caused by extended spectrum beta-lactamases producing Enterobacteriaceae. The company was founded by Nathaniel Eames David, Floyd E. Romesberg, and Peter G. Schultz in June 2002 and is headquartered in South San Francisco, CA. | Health Technology |
| The Genentech Foundation | Miscellaneous |
